119 related articles for article (PubMed ID: 32567280)
1. [Construction, expression and purification of a mammalian secretory recombinant fusion protein rPC].
Li C; Xie Y; Cao J; Shao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):969-978. PubMed ID: 32567280
[TBL] [Abstract][Full Text] [Related]
2. Crystallographic approaches to study the interaction modes of PD-1- and CTLA-4-blocking antibodies.
Nomura N; Nomura Y; Sato Y; Iwata S
Methods Enzymol; 2019; 629():383-399. PubMed ID: 31727250
[TBL] [Abstract][Full Text] [Related]
3. Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.
Zhang W; Shi L; Zhao Z; Du P; Ye X; Li D; Cai Z; Han J; Cai J
Cancer Chemother Pharmacol; 2019 May; 83(5):911-920. PubMed ID: 30848330
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
5. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
6. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
[TBL] [Abstract][Full Text] [Related]
7. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
Wei J; Nduom EK; Kong LY; Hashimoto Y; Xu S; Gabrusiewicz K; Ling X; Huang N; Qiao W; Zhou S; Ivan C; Fuller GN; Gilbert MR; Overwijk W; Calin GA; Heimberger AB
Neuro Oncol; 2016 May; 18(5):639-48. PubMed ID: 26658052
[TBL] [Abstract][Full Text] [Related]
8. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
9. Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis.
Wang B; Qin L; Ren M; Sun H
Cell Physiol Biochem; 2018; 49(1):260-270. PubMed ID: 30138920
[TBL] [Abstract][Full Text] [Related]
10. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
11. Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein (P-V).
Qian N; Gao L; Dong L; Liu H; Fu J; Meng D; Gao X; Zhang J; Gao Y; Song H
Protein Expr Purif; 2015 May; 109():1-6. PubMed ID: 25616235
[TBL] [Abstract][Full Text] [Related]
12. Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy.
Lázár-Molnár E; Scandiuzzi L; Basu I; Quinn T; Sylvestre E; Palmieri E; Ramagopal UA; Nathenson SG; Guha C; Almo SC
EBioMedicine; 2017 Mar; 17():30-44. PubMed ID: 28233730
[TBL] [Abstract][Full Text] [Related]
13. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
14. [Construction of recombinant adenovirus vector expressing extracellular domain of TbetaR-II-RANTES fusion gene and its anti-tumor effects].
Wang XD; Liu H; Cao S; Li H; Ren XB; Hao XS
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):405-10. PubMed ID: 17974270
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Das R; Verma R; Sznol M; Boddupalli CS; Gettinger SN; Kluger H; Callahan M; Wolchok JD; Halaban R; Dhodapkar MV; Dhodapkar KM
J Immunol; 2015 Feb; 194(3):950-9. PubMed ID: 25539810
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors for cancer treatment.
Park J; Kwon M; Shin EC
Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
[TBL] [Abstract][Full Text] [Related]
17. Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Non-Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database.
Deng L; Gyorffy B; Na F; Chen B; Lan J; Xue J; Zhou L; Lu Y
J Thorac Oncol; 2015 Jul; 10(7):1020-6. PubMed ID: 26134222
[TBL] [Abstract][Full Text] [Related]
18. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Rotte A
J Exp Clin Cancer Res; 2019 Jun; 38(1):255. PubMed ID: 31196207
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
